metir Blog

Anthropic's Claude Security plugin, a multi-agent vulnerability scanner for Claude Code, entered public beta on July 21, 2026. A complete guide to installing it, scanning a codebase, and turning findings into patches.

AMD's Advancing AI 2026 event brings the Instinct MI450 series, Helios racks and Zen 6 EPYC CPUs, backed by OpenAI, Meta, Oracle, Microsoft and a new Anthropic deal. A neutral look at what AMD must still prove against Nvidia.

Shield AI raised $1.5 billion at a $12.7 billion valuation, up 140% in a year. A neutral look at the round inside 2026's wider defense-AI funding wave, which crested in July.

Google, Anthropic, OpenAI and Microsoft now gate their most capable cyber models to governments and vetted partners. A neutral look at why, and what it means.

A July 2026 HCLTech study finds 90% of enterprises say generative and agentic AI are transforming workflows, but only 18% report significant revenue impact. A neutral look at why the gap exists and what closes it.

Block launched Buzz on July 21, 2026, an open-source, Nostr-based workspace where AI agents hold equal standing to humans. A neutral look at what that actually requires.

Google released Gemini 3.6 Flash, 3.5 Flash-Lite and 3.5 Flash Cyber on July 21, 2026. Here is what the token-efficiency and pricing numbers actually mean for the economics of running AI agents.

FLI's Summer 2026 AI Safety Index graded nine AI labs. Anthropic led with a C+, three labs failed, and reviewers say the leaders are retreating from earlier safety pledges.

Four frontier model launches in eight days pushed six AI labs above 50 on the Artificial Analysis Intelligence Index, up from two in early June, while price per task fell sharply. Here is what the compression actually means for buyers.

Nvidia is ramping the Vera Rubin architecture and selling entire 'AI factories,' not just chips. A neutral look at the Vera CPU and Rubin GPU, a 13,750-CPU, 27,500-GPU deal in Japan, and the power and memory limits behind the buildout.

OpenAI has reportedly discussed giving the US government a roughly 5% equity stake worth $43-50 billion, while advisers weigh delaying its IPO to 2027 rather than cut a $1 trillion target. Here is what is confirmed, what is reported, and what it means.

CuspAI raised a $450 million Series B at a $2.6 billion valuation on July 20, 2026, with Jeff Bezos, Nvidia, AMD and Meta among the backers. A neutral, analytical look at AI-driven materials discovery, why it is suddenly a magnet for capital, and what it can and cannot do yet.

CXMT priced an $8.6 billion Shanghai IPO in July 2026, oversubscribed 212 times, the largest semiconductor listing in mainland China's history. A neutral, analytical look at China's DRAM champion, the memory supercycle behind AI, and what the raise does and does not prove.

In 2026 the biggest tech companies are on track to spend close to $700 billion on AI infrastructure while returns lag and debt climbs. A neutral, analytical look at the capex-versus-revenue gap, why Oracle is cutting jobs to fund it, and how to read the supercycle-versus-bubble debate.

Alibaba announced Qwen 3.8 Max, a 2.4 trillion parameter open-weight model it says trails only Claude Fable 5. A neutral analysis of what was actually released, what the 'second only to Fable' claim rests on, and how it fits the 2026 open-weight race with Kimi K3.

On July 17, 2026, Apple reclaimed the most-valuable-company title from Nvidia by a margin of about $20 billion. A neutral analysis of what changed, why investors are rotating from the AI infrastructure layer toward distribution, and what the move does and does not prove.

Databricks is raising roughly $3 billion at a $188 billion valuation led by Coatue, a 40 percent step-up in five months. A neutral analysis of where the money is going, why the data and governance layer is attracting frontier-scale marks, and what the pace implies.

New 2026 research shows one malicious email can plant a persistent false memory in an AI agent that survives long after the email is deleted. A neutral, educational explainer on how memory poisoning works, why it is harder than ordinary prompt injection, and what mitigations exist.

Microsoft is preparing Project Perception, an AI cybersecurity platform that routes work across models from Microsoft, OpenAI, and Anthropic to keep continuous vulnerability scanning affordable. A neutral analysis of the design, the economics of model routing, and the open questions.

Moonshot AI's Kimi K3 is a 2.8 trillion parameter open-weights model that independent testing places at the frontier tier, priced like a Western mid-tier model rather than a bargain. A neutral, analytical look at the architecture, the benchmarks, and the pricing shift it signals.

TSMC posted record Q2 2026 revenue of $40.2 billion, raised its full-year outlook past 40% growth, and added $100 billion to its Arizona buildout. A neutral, analytical read on why the company's numbers are the clearest signal we have on whether the AI infrastructure cycle is accelerating or cooling.

Munich-based Helsing raised $1.8 billion at an $18 billion valuation, the largest defense-startup round in European history. A neutral, analytical look at why AI-first defense companies are commanding software-scale valuations, what the money is actually for, and the hard questions the category raises.

OpenAI unveiled a Broadcom-built inference chip named Jalapeño, Anthropic is reportedly in talks with Samsung, and TSMC's 2nm node just booked its first revenue. A neutral, analytical look at why the model labs are moving into silicon, what it changes, and what it does not.

OpenAI is shutting down its standalone Atlas browser less than a year after launch and folding Chat, Work and Codex into a single ChatGPT desktop app. A neutral, analytical look at the superapp strategy, why the browser was cut, and what consolidation means for users.

Chai Discovery raised $400 million at a $3.8 billion valuation as its AI models for antibody design reached the pipelines of the world's largest drugmakers. A neutral, analytical look at how generative AI is changing early drug discovery, what is proven, and what is still unproven.